Clinical trials
Completed trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
10,147 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 15 |
| 2002 | 16 |
| 2003 | 64 |
| 2004 | 88 |
| 2005 | 131 |
| 2006 | 211 |
| 2007 | 280 |
| 2008 | 393 |
| 2009 | 457 |
| 2010 | 542 |
| 2011 | 601 |
| 2012 | 633 |
| 2013 | 677 |
| 2014 | 652 |
| 2015 | 633 |
| 2016 | 590 |
| 2017 | 686 |
| 2018 | 617 |
| 2019 | 543 |
| 2020 | 540 |
| 2021 | 554 |
| 2022 | 436 |
| 2023 | 359 |
| 2024 | 225 |
| 2025 | 134 |
| 2026 | 39 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10,147 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 953 |
| Yonsei University | 691 |
| Samsung Medical Center | 439 |
| Asan Medical Center | 289 |
| AstraZeneca | 238 |
| Novartis Pharmaceuticals | 233 |
| Pfizer | 223 |
| GlaxoSmithKline | 215 |
| Hoffmann-La Roche | 199 |
| Chong Kun Dang Pharmaceutical | 197 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 391 |
| Carcinoma, Non-Small-Cell Lung | 267 |
| Hypertension | 258 |
| Breast Neoplasms | 244 |
| Stomach Neoplasms | 241 |
| Neoplasms | 193 |
| Diabetes Mellitus | 164 |
| Coronary Artery Disease | 160 |
| Carcinoma, Hepatocellular | 145 |
| Stroke | 140 |
Trials
Showing 1 to 25 of 10,147. Each trial links to its page on Pharma Observatory.
10,047 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.